oxaliplatincontaining

Oxaliplatin-containing refers to chemotherapy regimens that include oxaliplatin, a platinum-based anticancer drug. It is used primarily for colorectal cancer and is a component of commonly employed regimens such as FOLFOX, which combines folinic acid, 5-fluorouracil, and oxaliplatin, and CAPOX, which pairs capecitabine with oxaliplatin. In some settings, oxaliplatin-containing regimens are used for other gastrointestinal cancers as part of specific treatment protocols, with suitability determined by tumor type and stage.

Mechanism of action and use. Oxaliplatin forms platinum-DNA adducts that crosslink DNA and disrupt replication and transcription, leading to tumor cell death. It is active in tumors that express certain DNA repair capabilities and is typically given in cycles, often every 2 or 3 weeks depending on the regimen and patient tolerance. It is frequently combined with a fluoropyrimidine (5-FU or capecitabine) and, in some regimens, folinic acid to enhance efficacy.

Administration and monitoring. Oxaliplatin-containing regimens are given by intravenous infusion in a hospital or clinic setting. Dosing and cycle length depend on the specific regimen and patient factors. Patients are monitored with regular blood tests to check blood counts and organ function, along with assessment of symptoms. Neuropathy is a common and dose-related side effect, sometimes presenting as acute cold-induced paresthesias. Other adverse effects include fatigue, nausea, diarrhea or constipation, elevated liver enzymes, and, less commonly, hypersensitivity reactions. Dose modifications may be required for significant neuropathy or other toxicities.

Precautions. Use is avoided or delayed in individuals with severe neuropathy or a history of hypersensitivity to platinum compounds. Pregnancy should be avoided; potential drug interactions and cumulative neurotoxicity should be considered, particularly with other neurotoxic agents.